The licence allows for the collection, manufacturing, testing, storage and release for the supply of any commercial T-Cell product.
The Therapeutic Goods Administration (TGA) of Australia has grant...
Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, announced that they have signed a manufacturing service agreemen...
Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that it has entered into a Master Development and Commercialization Agreement with Kite, a G...
Collaboration to assess automated CAR-T cell therapy manufacturing at the point-of-care.
Sheba Medical Center at Tel Hashomer, the largest hospital in Israel and the Middle East region, and Swiss-b...
Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it has entered into a lease agreement to build an 82,00...
MaxCyte, the global cell-based medicines and life sciences company, announced that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial a...
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, announced that it has entered into a lease agreeme...
Proposed decision would provide nationwide consistency in CMS’s coverage of the innovative new cancer therapy, to improve patient access and ensure appropriate evidence generation.
The Centers for ...
NICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did not respond to two or more previous treatments.
The drug will be fun...
Brexit and the rise of nationalism in Europe could hinder patients’ access to pricey CAR-T therapies across Europe, a conference heard.
In England, the NHS, NICE and the government have joined forc...
Getting CAR-T cells to work in solid tumours is proving a tough nut to crack – and a conference heard details of a cutting-edge approach that could inform clinical trials in the future.
Kisaco Rese...
The first completed bio-banks will be used to develop more cost-effective, safe and efficacious cancer treatments.
TC BioPharm (TCB), a developer of CAR-T immuno-oncology products, including Gamma ...
Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to develop....
Following its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and gene manufacturing capabilities by offering to acquire CDMO CellforCure, manufacturers o...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK